| 0 (0%) | 06-28 18:07 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 198.69  |
1-year : | 207.19 |
| Resists | First : | 170.11 |
Second : | 177.38 |
| Pivot price | 166.36 |
|||
| Supports | First : | 158.35 | Second : | 131.74 |
| MAs | MA(5) : | 167.82 |
MA(20) : | 167.36 |
| MA(100) : | 158.26 |
MA(250) : | 145.92 |
|
| MACD | MACD : | -0.8 |
Signal : | -1 |
| %K %D | K(14,3) : | 55.1 |
D(3) : | 57.1 |
| RSI | RSI(14): 49.1 |
|||
| 52-week | High : | 179.52 | Low : | 116.41 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ BAP ] has closed below upper band by 45.7%. Bollinger Bands are 1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 171.32 - 172.35 | 172.35 - 173.12 |
| Low: | 163.6 - 164.95 | 164.95 - 165.96 |
| Close: | 165.28 - 167.28 | 167.28 - 168.76 |
Fri, 22 Sep 2023
Abpro inks SPAC deal to fund bispecific R&D years after axed IPO - Fierce Biotech
Wed, 21 Sep 2022
Celltrion partners with Abpro of U.S. for breast cancer treatment development - Yonhap News Agency
Wed, 21 Sep 2022
Celltrion/Abpro, Merck/Nerviano and more Unite against Cancer - BioSpace
Wed, 21 Sep 2022
Abpro Finalizes Strategic Partnership with Celltrion for Worldwide Development and Commercialization of a Cancer ... - Business Wire
Mon, 16 Nov 2020
Abpro Announces Peer-Reviewed Publication Demonstrating Efficacy of its Neutralizing Antibody Therapeutic Against ... - GlobeNewswire
Tue, 20 Oct 2020
Abpro Announces Completion of Dosing in Phase 1 Study of its Neutralizing Antibody Therapeutic, ABP 300 for ... - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 80 (M) |
| Shares Float | 52 (M) |
| Held by Insiders | 34.4 (%) |
| Held by Institutions | 72.3 (%) |
| Shares Short | 555 (K) |
| Shares Short P.Month | 535 (K) |
| EPS | 15.96 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 408.32 |
| Profit Margin | 30 % |
| Operating Margin | 36.9 % |
| Return on Assets (ttm) | 2 % |
| Return on Equity (ttm) | 15.8 % |
| Qtrly Rev. Growth | 1.8 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 203.52 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -16.4 % |
| Operating Cash Flow | 1,810 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 10.46 |
| PEG Ratio | 8 |
| Price to Book value | 0.4 |
| Price to Sales | 0.82 |
| Price to Cash Flow | 7.33 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|